pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 29·1 min read
save

FTC sues Hims & Hers for misleading consumers and privacy violations

Jul 29, 2026·read at STAT ↗RegulatoryNegative

The Federal Trade Commission, joined by Utah and California, filed a lawsuit against Hims & Hers, a direct-to-consumer telehealth provider, alleging deceptive business practices.

The complaint says the company misled users about sharing their health data with third parties such as Meta and Snap, and did not clearly disclose that completing a medical questionnaire enrolls patients in an automatically renewing medication subscription.

The suit also claims patients have little opportunity to review or consent to the provider’s recommended treatments and that the platform makes it difficult to cancel or modify services.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Hims misled consumers and violated their privacy, FTC alleges in a lawsuit”

read at STAT ↗
603 words · retrieved Jul 29
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLYRISING

related stories

  • Jul 31STAT+: Up and down the ladder: The latest comings and goingsSTAT
  • Jul 31STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and moreSTAT
  • Jul 30STAT+: Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuelsSTAT
  • Jul 29NSF testing new Ph.D. model giving trainees academic and industry experienceSTAT
  • Jul 28Eli Lilly tops new biopharma ranking on launch success, development speedFierce Biotech